[PDF][PDF] Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study
A Younes, A Sureda, D Ben-Yehuda… - Journal of Clinical …, 2012 - researchgate.net
A Younes, A Sureda, D Ben-Yehuda, PL Zinzani, TC Ong, HM Prince, SJ Harrison…
Journal of Clinical Oncology, 2012•researchgate.netPanobinostat in Patients With Relapsed/Refractory Hodgkin’s Lymphoma After Autologous
Stem-Cell Transplantation: Results of a Page 1 Panobinostat in Patients With Relapsed/Refractory
Hodgkin’s Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II
Study Anas Younes, Anna Sureda, Dina Ben-Yehuda, Pier Luigi Zinzani, Tee-Chuan Ong, H.
Miles Prince, Simon J. Harrison, Mark Kirschbaum, Patrick Johnston, Jennifer Gallagher,
Christophe Le Corre, Angela Shen, and Andreas Engert See accompanying editorial on page …
Stem-Cell Transplantation: Results of a Page 1 Panobinostat in Patients With Relapsed/Refractory
Hodgkin’s Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II
Study Anas Younes, Anna Sureda, Dina Ben-Yehuda, Pier Luigi Zinzani, Tee-Chuan Ong, H.
Miles Prince, Simon J. Harrison, Mark Kirschbaum, Patrick Johnston, Jennifer Gallagher,
Christophe Le Corre, Angela Shen, and Andreas Engert See accompanying editorial on page …
Purpose
Hodgkin’s lymphoma (HL) has no standard of care for patients who are relapsed or refractory to autologous stem-cell transplantation (ASCT). This phase II study examined safety and activity of panobinostat in this population.
researchgate.net